Sangamo Therapeutics (SGMO) 10-Q 2017 Q1 Quarterly report

Exhibit 32.1

Certification Pursuant to 18 U.S.C. §1350, as Adopted

Pursuant to §906 of the Sarbanes-Oxley Act of 2002

Each of the undersigned hereby certifies pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 in his capacity as an officer of Sangamo Therapeutics, Inc. (the “Company”), that:

(1) the Quarterly Report of the Company on Form 10-Q for the quarterly period ended March 31, 2017, as filed with the Securities and Exchange Commission (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Alexander D. Macrae 

Alexander D. Macrae

President and Chief Executive Officer

(Principal Executive Officer)

Date: May 10, 2017

/s/ Kathy Y. Yi

Kathy Y. Yi

Senior Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

Date: May 10, 2017